DelveInsight’s “Parkinson’s Disease Levodopa-Induced Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Parkinson’s Disease Levodopa-Induced Dyskinesia, historical and forecasted epidemiology as well as the Parkinson’s Disease Levodopa-Induced Dyskinesia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Parkinson’s Disease Levodopa-Induced Dyskinesia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Parkinson’s Disease Levodopa-Induced Dyskinesia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson’s Disease Levodopa-Induced Dyskinesia Market Insights

Parkinson’s Disease Levodopa-Induced Dyskinesia Overview

Parkinson’s disease (PD) is a life-threatening progressive neurodegenerative disease characterized by severe locomotor impairments, including bradykinesia, tremor, and rigidity. Other abnormalities associated with PD are cognitive defects, psychiatric abnormalities, and neurodegenerative implications of levodopa-induced dyskinesia (LID).

Some of the key facts of the Parkinson’s Disease Levodopa-Induced Dyskinesia Market Report: 

• The Parkinson’s Disease Levodopa-Induced Dyskinesia market size is expected to reach approximately USD 2,000 Million with a significant CAGR during the study period (2019-2032)
• In 2021, the total number of PD-LID cases in the 7MM were nearly 584,400, of which the highest number of cases were observed in the United States
• There were more than 287,000 cases of PD-LID in the United States in 2021, which are expected to rise during the forecast period (2022–2032)
• The number of PD-LID cases were the highest in Germany (more than 67,000 cases), followed by France (about 56,000 cases) among EU4 and the UK in 2021, which are expected
• In October 2020, Integrative Research Laboratories AB (IRLAB) announced that the FDA has accepted its IND for mesdopetam (IRL790), to conduct a Phase II/III clinical trial of PD patients on levodopa
• Key Parkinson’s Disease Levodopa-Induced Dyskinesia Companies: PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, and others 
• Key Parkinson’s Disease Levodopa-Induced Dyskinesia Therapies: KETARX, NLX-112, JM-010, and others
• The Parkinson’s Disease Levodopa-Induced Dyskinesia epidemiology based on type-specific cases analyzed that there are three types of PD-LID: peak-dose dyskinesia, off-period dystonia, and diphasic dyskinesia, among which peak-dose dyskinesia accounted for the highest number of cases, whereas diphasic dyskinesia during the forecast period

Get a Free sample for the Parkinson’s Disease Levodopa-Induced Dyskinesia Market Report – 

https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market

Key benefits of the Parkinson’s Disease Levodopa-Induced Dyskinesia Market report:

1. Parkinson’s Disease Levodopa-Induced Dyskinesia market report covers a descriptive overview and comprehensive insight of the Parkinson’s Disease Levodopa-Induced Dyskinesia Epidemiology and Parkinson’s Disease Levodopa-Induced Dyskinesia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Parkinson’s Disease Levodopa-Induced Dyskinesia market report provides insights on the current and emerging therapies.
3. Parkinson’s Disease Levodopa-Induced Dyskinesia market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Parkinson’s Disease Levodopa-Induced Dyskinesia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Parkinson’s Disease Levodopa-Induced Dyskinesia market.

Download the report to understand which factors are driving Parkinson’s Disease Levodopa-Induced Dyskinesia epidemiology trends @ Parkinson’s Disease Levodopa-Induced Dyskinesia Epidemiological Insights 

Parkinson’s Disease Levodopa-Induced Dyskinesia Market  

The dynamics of the Parkinson’s Disease Levodopa-Induced Dyskinesia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Parkinson’s Disease Levodopa-Induced Dyskinesia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Parkinson’s Disease Levodopa-Induced Dyskinesia Epidemiology Segmentation:

The Parkinson’s Disease Levodopa-Induced Dyskinesia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Parkinson’s Disease Levodopa-Induced Dyskinesia
• Prevalent Cases of Parkinson’s Disease Levodopa-Induced Dyskinesia by severity
• Gender-specific Prevalence of Parkinson’s Disease Levodopa-Induced Dyskinesia
• Diagnosed Cases of Episodic and Chronic Parkinson’s Disease Levodopa-Induced Dyskinesia

Parkinson’s Disease Levodopa-Induced Dyskinesia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson’s Disease Levodopa-Induced Dyskinesia market or expected to get launched during the study period. The analysis covers Parkinson’s Disease Levodopa-Induced Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parkinson’s Disease Levodopa-Induced Dyskinesia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Parkinson’s Disease Levodopa-Induced Dyskinesia market share @ Parkinson’s Disease Levodopa-Induced Dyskinesia market forecast 

Parkinson’s Disease Levodopa-Induced Dyskinesia Therapies and Key Companies

• KETARX: PharmaTher Inc.
• NLX-112: Neurolixis SAS/Gala laboratories
• JM-010: Bukwang Pharmaceutical/Contera Pharma

Parkinson’s Disease Levodopa-Induced Dyskinesia Market Strengths

• The concept of ‘drug-repurposing’ has been used in drug development for LID for many years, for instance, amantadine was initially licensed for viral infections, and clinical observation noted improved symptoms in PD subjects using the drug for influenza
• The constant researches on novel AI-driven computational approaches and improvements in formulating long-acting L-DOPA preparations or infusion systems offer means to drive drug discovery, which may further lower the incidence of LID

Scope of the Parkinson’s Disease Levodopa-Induced Dyskinesia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Parkinson’s Disease Levodopa-Induced Dyskinesia Companies: PharmaTher Inc., Neurolixis SAS, Gala laboratories, Bukwang Pharmaceutical, Contera Pharma, and others
• Key Parkinson’s Disease Levodopa-Induced Dyskinesia Therapies: KETARX, NLX-112, JM-010, and others
• Parkinson’s Disease Levodopa-Induced Dyskinesia Therapeutic Assessment: Parkinson’s Disease Levodopa-Induced Dyskinesia current marketed and Parkinson’s Disease Levodopa-Induced Dyskinesia emerging therapies
• Parkinson’s Disease Levodopa-Induced Dyskinesia Market Dynamics: Parkinson’s Disease Levodopa-Induced Dyskinesia market drivers and Parkinson’s Disease Levodopa-Induced Dyskinesia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Parkinson’s Disease Levodopa-Induced Dyskinesia Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Levodopa-Induced Dyskinesia Market Access and Reimbursement 

Parkinson’s Disease Levodopa-Induced Dyskinesia Market Unmet Needs

• Unclear and inaccurate patho-mechanisms
• Lack of standardized diagnostic approaches
• Economic burden and health-related quality of life (HR-QoL) deterioration
• Challenges in the current management pattern

Table of Contents 

1. Parkinson’s Disease Levodopa-Induced Dyskinesia Market Report Introduction

2. Executive Summary for Parkinson’s Disease Levodopa-Induced Dyskinesia

3. SWOT analysis of Parkinson’s Disease Levodopa-Induced Dyskinesia

4. Parkinson’s Disease Levodopa-Induced Dyskinesia Patient Share (%) Overview at a Glance

5. Parkinson’s Disease Levodopa-Induced Dyskinesia Market Overview at a Glance

6. Parkinson’s Disease Levodopa-Induced Dyskinesia Disease Background and Overview

7. Parkinson’s Disease Levodopa-Induced Dyskinesia Epidemiology and Patient Population

8. Country-Specific Patient Population of Parkinson’s Disease Levodopa-Induced Dyskinesia 

9. Parkinson’s Disease Levodopa-Induced Dyskinesia Current Treatment and Medical Practices

10. Parkinson’s Disease Levodopa-Induced Dyskinesia Unmet Needs

11. Parkinson’s Disease Levodopa-Induced Dyskinesia Emerging Therapies

12. Parkinson’s Disease Levodopa-Induced Dyskinesia Market Outlook

13. Country-Wise Parkinson’s Disease Levodopa-Induced Dyskinesia Market Analysis (2019–2032)

14. Parkinson’s Disease Levodopa-Induced Dyskinesia Market Access and Reimbursement of Therapies

15. Parkinson’s Disease Levodopa-Induced Dyskinesia Market Drivers

16. Parkinson’s Disease Levodopa-Induced Dyskinesia Market Barriers

17.  Parkinson’s Disease Levodopa-Induced Dyskinesia Appendix

18. Parkinson’s Disease Levodopa-Induced Dyskinesia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Parkinson’s Disease Levodopa-Induced Dyskinesia treatment, visit @ Parkinson’s Disease Levodopa-Induced Dyskinesia Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services